Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCTH
3051
DELISTED
Delcath Systems Inc
DCTH
| $147K | ﹤0.01% |
160,128
+100,214
| +167% | +$194K |
|
3052
Maui Land & Pineapple Co
MLP
$352M
| $146K | ﹤0.01% |
20,300
+2,629
| +15% | +$17.9K |
|
3053
Halozyme
HALO
$9.9B
| $145K | ﹤0.01% |
14,700
-85,300
| -85% | -$934K |
|
|
PW
3054
Power REIT
PW
$3.18M
| $145K | ﹤0.01% |
2,060
+250
| +14% | +$20.2K |
|
|
CASI
3055
DELISTED
CASI Pharmaceuticals
CASI
| $144K | ﹤0.01% |
12,480
+6,350
| +104% | +$86.9K |
|
3056
Marathon Digital Holdings
MARA
$4.07B
| $144K | ﹤0.01% |
5,250
+3,806
| +264% | +$125K |
|
3057
ImmunityBio
IBRX
$7.27B
| $140K | ﹤0.01% |
+24,500
| New | +$163K |
|
|
STLY
3058
DELISTED
Stanley Furniture Co Inc
STLY
| $140K | ﹤0.01% |
156,000
+19,556
| +14% | +$24.1K |
|
|
FNJN
3059
DELISTED
Finjan Holdings, Inc.
FNJN
| $138K | ﹤0.01% |
122,200
+13,700
| +13% | +$18.8K |
|
3060
ReWalk Robotics
LFWD
$19.9M
| $136K | ﹤0.01% |
23
+14
| +156% | +$107K |
|
3061
Global Net Lease
GNL
$1.87B
| $132K | ﹤0.01% |
5,600
-36,600
| -87% | -$838K |
|
|
NHLD
3062
DELISTED
National Holdings Corporation
NHLD
| $132K | ﹤0.01% |
49,200
-70,900
| -59% | -$223K |
|
|
HTGM
3063
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $130K | ﹤0.01% |
323
+79
| +32% | +$31.5K |
|
3064
Atossa Therapeutics
ATOS
$23.3M
| $128K | ﹤0.01% |
505
+275
| +120% | +$85.7K |
|
|
ECYT
3065
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $128K | ﹤0.01% |
50,100
-138,900
| -73% | -$399K |
|
|
YGE
3066
DELISTED
Yingli Green Energy Holding Comp
YGE
| $128K | ﹤0.01% |
49,389
+20,400
| +70% | +$70.3K |
|
|
SVT
3067
DELISTED
Servotronics
SVT
| $127K | ﹤0.01% |
+12,600
| New | +$131K |
|
3068
Savara
SVRA
$1.09B
| $126K | ﹤0.01% |
20,697
+746
| +4% | +$4.69K |
|
|
BYBK
3069
DELISTED
Bay Bancorp, Inc.
BYBK
| $126K | ﹤0.01% |
+19,100
| New | +$112K |
|
|
PGLC
3070
DELISTED
Pershing Gold Corporation. Common Stock
PGLC
| $126K | ﹤0.01% |
38,400
-244,400
| -86% | -$949K |
|
3071
Stabilis Solutions
SLNG
$91.3M
| $125K | ﹤0.01% |
10,088
+488
| +5% | +$7.41K |
|
|
SUNW
3072
DELISTED
Sunworks, Inc.
SUNW
| $125K | ﹤0.01% |
+8,924
| New | +$158K |
|
3073
Enlivex Ltd
ENLV
$37M
| $124K | ﹤0.01% |
198
+57
| +40% | +$48.3K |
|
|
BLPH
3074
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $124K | ﹤0.01% |
15,940
+12,240
| +331% | +$170K |
|
|
RLOG
3075
DELISTED
Rand Logistics, Inc.
RLOG
| $124K | ﹤0.01% |
149,600
+10,000
| +7% | +$8.54K |
|
Similar funds
Renaissance Technologies's Q4 2016 Portfolio in Review
As of Q4 2016, Renaissance Technologies held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Renaissance Technologies deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Renaissance Technologies's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Renaissance Technologies added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Renaissance Technologies's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Renaissance Technologies fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Renaissance Technologies's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Renaissance Technologies opened 418 new positions and closed 494 in Q4 2016.
- Renaissance Technologies's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.